Clinical Trials Logo

Filter by:
  • Withdrawn  
  • Page [1]
NCT ID: NCT04387240 Withdrawn - Clinical trials for Corona Virus Infection

Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19

Start date: January 2022
Phase: Phase 2
Study type: Interventional

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. At this time, there are no specific vaccines or treatments for COVID-19. However, there are many ongoing clinical trials evaluating potential treatments Drugs used to treat malaria infection has shown to be beneficial for many other diseases, including viral infections. In this Clinical trial, Investigators will evaluate the effect of Artemisinin / Artesunate on morbidity of COVID-19 patients in decreasing the course of the disease and viral load in symptomatic stable positive swab COVID-19 patients. Investigators are hypothesizing that due to the antiviral properties of this drug it will help as a treatment for the COVID -19 patients. In improving their condition and clearing the virus load,

NCT ID: NCT04264806 Withdrawn - Clinical trials for Myelodysplastic Syndromes

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Start date: May 6, 2021
Phase: Phase 2
Study type: Interventional

The purpose of the study is to compare overall response rate (ORR) between treatment groups in participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for Hematopoietic Stem Cell Transplantation (HSCT).

NCT ID: NCT04238390 Withdrawn - Clinical trials for Bacteremia Caused by Gram-Negative Bacteria

Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection

MERINO III
Start date: January 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether ceftolozane-tazobactam is as effective as meropenem with respect to 30 day mortality in the treatment of bloodstream infection due to third-generation cephalosporin non-susceptible Enterobacterales or a known chromosomal AmpC-producing Enterobacterales (Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp. or Serratia marcescens).

NCT ID: NCT03759080 Withdrawn - Motor Activity Clinical Trials

Mental Practice Versus Proprioceptive Neuromuscular Facilitation on Strength of Upper Limb

Start date: May 8, 2018
Phase: N/A
Study type: Interventional

The effects of mental practice combined with proprioceptive neuromuscular facilitation on muscle strength of upper limb were measured in 60 healthy students Subjects were randomly assigned to either proprioceptive neuromuscular facilitation (PNF) group or mental practice (MP) group. PNF group: 30 individuals, these subjects received only PNF training. MP: 30 individuals, these subjects received mental practice.

NCT ID: NCT03468361 Withdrawn - Hypertension Clinical Trials

Diuretic Effect Evaluation of Petroselinum Crispum (Parsley) in Hypertensive Patients

DEEP
Start date: March 1, 2018
Phase: N/A
Study type: Interventional

The use of alternative therapy, particularly herbal treatment is becoming prevalent among patients. Many herbs are in-use for various ailments such as diabetes, digestive problems, fever, hepatitis and hypertension etc. The common belief is, herbs are safe and easy to access as compared to conventional therapy, however, most of the studies reported different side effects which may be toxic at times. These adverse effects are mostly due to incorrect use or lack of patient education. Parsley is a plant with antioxidant, diuretic and antimicrobial properties. Literature reported use of parsley as a diuretic by different communities in throughout the world. In vitro studies in animal have also reported the diuretic effect as well as proposed mechanisms for the use of parsley as diuretic however none of the studies have been conducted to investigate the diuretic effect of parsley in humans. This study aims to evaluate the diuretic and hence antihypertensive effect of parsley in hypertensive patients.

NCT ID: NCT02190799 Withdrawn - Clinical trials for Respiratory Distress Syndrome (& [Hyaline Membrane Disease])

Anti-MERS-CoV Convalescent Plasma Therapy

Start date: May 2014
Phase: Phase 2
Study type: Interventional

Since the first report of the Middle East Respiratory Syndrome Corona virus (MERS- CoV) in September 2012, more than 800 cases have been reported to the World Health Organization (WHO) with substantial mortality.

NCT ID: NCT01170507 Withdrawn - Clinical trials for Vitamin D Deficiency

Magnitude of Changes in 25 OH Vitamin D3 Levels After Vitamin D3 Supplementation

Start date: December 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Vitamin D deficiency is common world wide. 25 OH vitamin D level is the best indicator of vitamin D status. The determination of the appropriate dose of vitamin D supplement is essential for management of vitamin D deficiency as well as for designing vitamin D fortification programs. The increments in 25 OH vitamin D levels following various doses of vitamin D supplement for different genders, body weights, and starting 25 OH vitamin D level have not been well defined. The time course of depletion of repleted vitamin D stores is also not known. The investigators plan to conduct a double blind randomized study on 9 cohorts to determine levels of 25 OH vitamin D following supplementation with different doses of vitamin D3 for 5 months and their withdrawal for 3 months.

NCT ID: NCT01007474 Withdrawn - Bradycardia Clinical Trials

One Hospital ClinicalService Project

OHCS
Start date: January 2004
Phase:
Study type: Observational

The One Hospital ClinicalService Project is an integrated system composed by a network of International Hospital Departments, a clinical data repository and a shared environment for the collection, management, analysis and reporting of clinical and diagnostics data from patients treated by Medtronic therapies or patients wearing Medtronic implantable devices used within their intended use. The One Hospital ClinicalService is composed by a suite of systematic, data-guided activities designed to bring about immediate improvements in health delivery in particular settings. Data are prospectively collected. An independent committee of physicians prospectively identifies key clinical questions on a yearly basis for development of quality improvement activities, analyses and publications. A charter, approved by Hospital Istitutional Review Boards or other Hospital entities, assigns the ownership of data to the centers and governs the conduct of the project and the relationship of the scientific committee and Medtronic. Hospital is the data controller, while Medtronic is the data processor on behalf of the Hospital. Data collected for quality improvement purposes may be mined to perform clinical research.